The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study
Blood (2018) 132 (Supplement 1): 3140.
Currently there are no citedby results. Try again later.
